Accumulating evidence suggests that lack of balance between proliferation and apoptosis may lead to clonal expansion and cancer emergence. In diffuse large B cell lymphoma (DLBCL), survivin expression by tumor cells has been recently described as a poor prognostic marker. We assessed the relationship between survivin gene up-regulation and several other factors involved in either cell cycle or apoptosis control. The expression of 34 genes from 27 cases of DLBCL with typical IPI factor-related poor prognostic outcome was analyzed by RNase protection assay. Using non-neoplastic tissues and low grade lymphomas as control, survivin expression was high in 80% of the cases without significant relation to patient overall survival (P = 0.64). However, the expression of several genes encoding for cell cycle inhibitors, cyclins, Bcl-2 or IAP family factors was significantly associated with the survivin up-regulation. Gene expression profiling showed that both survivin and cyclin B expression can define two subgroups of DLBCL: the previously described germinal center-like and activated B-like lymphomas, determined by protein expression analysis. We also identified a preferential survivin-cyclin B relationship (P = 0.017), suggesting that cyclin B over-expression, when linked to survivin over-expression in aggressive forms of lymphoma, might demonstrate a specific G2/M transition promotion. Leukemia (2002) 16, 726-735.
Introduction
B cell non-Hodgkin's lymphomas (NHL) are a group of highly heterogeneous lymphoproliferative disorders. Despite steady improvement in their classification, patients with the same diagnosis can have markedly different clinical courses. CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) regimen has significantly improved the outcome of patients with intermediate grade or high grade NHL and remains the standard treatment. 1, 2 Nevertheless, more than 50% of patients never reach remission; they eventually develop resistance to chemotherapy and die of the disease.
Diffuse large B cell lymphoma (DLBCL) is an aggressive malignancy of mature B cells accounting for roughly 40% of NHL cases. Since the prognosis remains uncertain, several biologically based prognostic indicators have been proposed in the last decade in addition to the International Prognostic Index or IPI. 3, 4 None have proved completely effective and more independent factors have yet to be identified and confirmed in large multivariate analyses. [5] [6] [7] Recently, a major contribution to our knowledge of the lymphoma pathogenesis was made through the development of cDNA microarrays specially designed to investigate normal and malignant lymphocyte biology. 8 In order to explore DLBCL, a total of 17 856 cDNA were evaluated and several million separate measurements were collected and finally clustered. 8, 9 In absence of reliable morphological, clinical, immunohistochemical and genetic indicators that could be used to recognize subclasses of DLBCL and lead to a different therapeutic approach for patients, they were able to distinguish two subgroups of lymphomas: one group characterized by both a good prognosis and a B cell with germinal center signature and the other characterized by a significantly worse overall survival with an activated B cell-like signature. 9 Accumulating evidence suggests that abnormalities in cell cycle and programmed cell death (apoptosis) are hallmarks of clonal expansion leading to cancer emergence. [10] [11] [12] Such abnormalities may frequently induce drug and/or radiation resistance in NHL, as we and others have shown for Tp53 gene mutations. [13] [14] [15] The expression of several cell cycle and apoptosis regulator genes is modified in lymphoid neoplasms, ie cyclin D1 in mantle NHL or bcl-2 in follicular and some large B cell NHL, supporting the idea that cancer results from lack of balance between cell proliferation and apoptosis. Apoptosis is also a pathway shared by cytotoxic agents. 10, 16 Promotion of proliferation, secondary to oncogenic activation such as cyclin over-expression, associated with blockage of cell death by ectopic bcl-2 expression, for example, significantly promotes cancer development. [17] [18] [19] In this context, the transcriptional control of cyclin B and protein kinase cdc2, two major regulators of the G2 transition and checkpoint, is crucial for mitotic initiation regulation. [20] [21] [22] Increased resistance to apoptosis is the most efficient way for transformed cells to escape death. The Bcl-2 family proteins are, in this context, major cancer targets, since they inhibit or promote apoptosis by interfering with caspase cascade activation. 23 The caspase cascade is a protease-chain which is another potential source of cancer resistance. [24] [25] [26] Therefore, caspase inhibitors such as inhibitor of apoptosis proteins (IAP) may play a role in oncogenesis. The strongest evidence of IAP involvement in cancer has been found for the IAP called survivin, which has recently been identified as an independent prognostic factor for the outcome of DLCBL. 27, 28 Although not observed in healthy adult differentiated tissue, survivin is present in most cancers and might interfere with the cell cycle and apoptosis. [29] [30] [31] Because large B cell lymphoma is a good cancer model for both proliferation and programmed cell death studies, we evaluated the gene expression levels of cell cycle and/or apoptosis control factors potentially associated with the upregulation of survivin. The mRNA expression of a panel of 34 genes from 27 well-characterized cases of DLBCL was assessed by RNase protection assay. Survivin expression was largely found up-regulated compared to normal tissues and associated with the modified expression of several other genes. Interestingly, a preferential relationship between survivin and cyclin B expression was identified, suggesting that both factors act through a shared mitotic promotion.
Materials and methods

Patients
A total of 27 cases of diffuse large B cell lymphoma, classified according to the WHO 2001 classification of Lymphoid Neoplasms was selected for the study. 32 To keep the material as homogeneous as possible, we included in the series only the centroblastic subtype of this lymphoma; therefore, all the cases fulfilled either the criteria of large noncleaved cell lymphoma according to the Lukes-Collins classification or the criteria of centroblastic lymphoma according to the Kiel classification. 33, 34 Only lymph nodes were used in our study, except for case PG1: the biopsy was performed on his abdominal bulky tumor. The samples collected between 1996 and 1999 were obtained from the frozen tissue bank of the Pathology Laboratory of the Jean Minjoz University Hospital (Besançon, France). The design of our study was in agreement with the general policy of our University Hospital concerning research on human samples obtained for diagnosis. Paraffin sections performed in the vicinity of the sample used for RNA extraction showed that the proportion of non-neoplastic cells never exceeded 10% in the tumor area. Seven DLBCL cases presented a low grade lymphoma background and were classified as transformed low grade lymphomas. The initial disease in this group was classified either as lymphoplasmacytoid lymphoma (cases C13, C19 and C21) or follicular lym- Leukemia phoma (cases PG2, C1, C18 and C20) according to previously described criteria. 32 The Ann Arbor stage of the tumor revealed that four patients (PG1, PG2, C15, C23) presented a bulky staging (largest tumor size у10 cm). All cases were immunoreactive to B cell antigens CD20 and either CD19 or CD22, and often to immunoglobulin as well. Clinical characteristics are presented in Table 1 . Briefly, 11 of the patients were female, 16 men; age at diagnosis ranged from 16 to 90 years (median, 59 years).
Eight non-neoplastic lymph nodes from healthy patients were included in our study as negative controls. All these cases were classified as immunoreactive adenopathies and none of the patients subsequently underwent specific treatment or developed disease from the immune system. Six follicular lymphoma lymph nodes were used for comparison with the DLBCL cases. Five cases were classified as grade I follicular lymphomas and one case was a grade II follicular lymphoma, according to the WHO 2001 classification of Lymphoid Neoplasms. 32 Briefly, at initial diagnosis of the patients, age ranged from 56 to 70 years (median, 63 years); all the cases except one were stage IV disease with normal blood LDH levels and the median follow up was 4 years. Three patients from the stage IV subgroup presented a disease progression and died of a chemotherapy resistant high grade lymphoma.
Total RNA extraction
The frozen lymph node sections were homogenized for 90 s in a vibration grinding mill (Mikro dismembrator U, Braun, Germany), using N 2 -frozen Teflon shaking containers and grinding balls. The disintegrated tissues were used for RNA extraction.
Total RNA was extracted from samples with TRIzol reagent (GIBCO BRL, Life Technologies, Cergy Pontoise, France) according to a modified guanidine-thiocyanate method; 35 then, chloroform extraction, isopropanol precipitation and quantification by spectrophotometry were performed.
RNase protection assay
Ten g of RNA were analyzed by RNase Protection Assay (RPA) with Riboquant kits (Pharmingen, San Diego, CA, USA). The hCC-2 and hCYC-1 kits simultaneously detected and quantified mRNA encoding for human cell cycle regulators divided into cyclins and cyclin-dependent kinase inhibitors: cyclin A, A1, B, C, D1, D2, D3, Rb p105 , Rb p130 , Rb p107 and p57, p53, p27, p21, p19, p18, p16, p14/15. The hAPO2c and hAPO5c panels explored simultaneously the mRNA encoding for human apoptosis regulators which belong to bcl-2 and IAP families: Bcl-w, Bcl-xS, Bcl-xL, Bfl-1, Bad, Bik, Bak, Bax, Bcl-2, Mcl-1 and XIAP, survivin, NAIP, cIAP-1, cIAP-2, TRPM-2. Each kit also detected and quantified mRNA encoding for two ubiquitous genes: GAPDH and L32. Briefly, riboprobes were synthesized by in vitro transcription, 36 using ␣ 32 P-UTP (NEN Life Science Products, Boston, MA, USA) and then purified by phenol-chloroform extraction and ethanol precipitation. Riboprobes-mRNA hybridization was performed overnight at 56°C. Samples were then digested by ribonucleases A and T1 (20 ng and 60 U/sample, respectively) for 45 min at 30°C. Then, after 15 min of proteinase K digestion at 37°C (12 g proteinase K/sample), phenol-chloroform extraction and ethanol precipitation were performed; the samples were resuspended in a formamide based loading dye and loaded on to a 5% polyacrylamide/7M urea denaturing gel. Following migration (40 W for 90 min), the gel was dried and exposed to Imaging Screen-CS and scanned using the BioRad GS-505 Molecular Imager system (BioRad, Marnes-la-Coquette, France). Intensity of gene bands and GAPDH mRNA were quantified with the MultiAnalyst software (BioRad). Data are expressed as the relative ratio of gene mRNA expression level to the GAPDH mRNA level.
Protein expression analysis
Different sets of antibodies were used for immunohistochemistry in order to verify the expression of cyclin B1 (clone 7A9; Novocastra Laboratories, Newcastle upon Tyne, UK), p53, Ki67 and Bcl-2 proteins (clone DO-7, Mib-1 and 124, respectively; Dako, Glostrup, Denmark) and to supplement the analysis by the detection of the germinal center proteins using Bcl-6 and CD10 monoclonal antibodies (clone P1F6 and 56C6, respectively, Novocastra Laboratories). A total of 12 cases were selected and divided in two, six samples with the lowest and six with the highest cyclin B mRNA expression and were tested for the expression of these proteins. Immunohistochemistry was performed on paraffin-embedded tissue sections. Antigen retrieval was performed in the case of antibodies against CD10, Ki67, Bcl-2, p53, cyclin B1 and Bcl-6 in a 99°C water bath for 40 min using either a citrate (pH6) or EDTA (pH8) buffer. 14 The remainder of the procedure was carried out with an automated immunostainer (Techmate 500; Dako) using the manufacturer's paraffin-slide protocol. In all cases, staining was performed with immunoperoxidase methods using a commercially available substrate kit (Universal ABC Detection Kit HK001; The Binding Site, Birmingham, UK).
Cyclin B1 + and Bcl-6 + neoplastic cell percentages were placed in one of the following categories: 0, less than 10%, 10 to 25%, 25 to 50%, 50 to 75%, and greater than 75%. Cyclin B1 staining was localized in both nuclei and cytosol whereas Bcl-6 was detected as a faint stain solely in the cytosol. Identical scoring was used for Ki67 staining. CD10 detection was considered as positive when the surface of the tumor cells was stained. Positive results were scored from 1+ to 3+ according to the number of positive-stained cells. Reactions for p53 were scored as negative if less than 10% of the nuclei was labeled. Bcl-2 staining was scored on a scale from 0 to 3+ after comparison with T cells as internal control. 14 
Statistical analysis
All the samples were analyzed twice independently for each mRNA detection panel and only reproducible data were considered. Interassay variability of the procedure was addressed in a previous work. 37 The calculated gene expression data were statistically analyzed with SPSS 10.0.5 (Windows Software; SPSS, Chicago, IL, USA). To test the significance of a mean difference for independent samples, we used Student's t statistic test. Concurrently, non-parametric analyses (Mann-Whitney U test) were used in order to rule out possible distribution problems. Probability of overall survival (OS) for patients was estimated with Kaplan and Meier's method. The univariate associations between individual clinical or biological features and overall survival were determined with the log-rank test. The correlation coefficients were calculated between pairs of variables using Spearman's rank test. The distance correlation matrix was used to cluster the positive gene expressions from the same gene family. Factors independently associated with survivin over-expression were identified in multivariate analysis by a logistic regression model. Only variables with the highest significance level in the univariate analysis were put in the model and were selected by a forward stepwise variable selection procedure. The change in the dependent variable (survivin) for a one-unit variation in the independent variable was given by Exp (B) expressed with its confidence interval (CI).
Results
Patient analysis
The 27 patients were treated according to standard protocols in our hematology department and after stratification according to the IPI index. With a median follow-up of 36 months, the average 3-year survival for all patients was 52% ( Figure 1 ) and disease-free survival was 48%. We found three of the four independent clinical prognostic factors included in the IPI (serum LDH Ͼnormal, performance status Ͼ1, age at diagnosis Ͼ60 years) significantly related to poor prognostic outcome (Figure 1) . No significant overall survival difference was found after stratification for primary or secondary disease (55% vs 42%, P = 0.21). 
Leukemia
Survivin gene expression analysis for the 27 DLBCL cases
Messenger RNA detection by RPA generated gene expression patterns ranged from an undetectable signal to a clear and thick band (Figure 2 ). The survivin mRNA was easily detected in the 27 tested high grade lymphomas with a quantified mean value of 63 ± 39.5 [3, 129] , compared to 23.5 ± 5.7 [18, 34] in the eight non-neoplastic tissues and 45 ± 21 [20, 67] Table 2 , increased survivin expression was found to be significantly associated with a higher expression of other IAP regulators, anti-apoptotic factors from the Bcl-2 family and cell cycle regulators (cyclin A, B and Rb p107 ).
Survivin up-regulation and gene expression profiling
In our study, mRNAs from eight hyperplastic lymph nodes were pooled and considered as a control sample. The mean
Figure 2
Survivin gene expression in 27 DLBCL tumoral tissues. Representative RNase protection assay result obtained after phosphoimager scanning: mRNA expression of IAP factors was analyzed using the hAPO5c panel. expression of the 34 analyzed genes for this control group presented a s.d. lower than 25% of the median for a vast majority of the genes, including all the relevant genes of our study, eg cyclin A and B, Bcl-w, Bcl-xL, Bfl-1, XIAP and survivin. The average expression of a single gene in our 27 DLBCL cases was expressed as relative gene expression using the ratio of mRNA expression between DLBCL and control cases. Thus, a score of 1 had an identical level of gene expression in both lymphoma cases and in the control tissues. Using this system we were able to design a gene expression profile for the 27 tested DLBCL based on 34 analyzed genes (Figure 3a) . The Bcl-xS gene was not included, since its expression could not be analyzed in all samples. All tested cyclin-dependent kinase inhibitor mRNAs were scored under 1. The other three types of factors showed contrasting results with weak or normal expression besides an increased expression for cyclin A and B, Bfl-1, Bik, XIAP, cIAP-1 and survivin (1.75 ± 1.1, 2.50 ± 1.5, 1.21 ± 1.27, 1.25 ± 0.89, 1.36 ± 1.22, 1.31 ± 0.72, 2.62 ± 1.65, respectively). Only six patients (cases PG1, PG3, PG4, C7, C10 and C22) presented a survivin gene expression scoring under or in the vicinity of 1 (6/27, P Ͻ 0.001).
Survivin and cyclin B presented the highest up-regulation, with a double peak in the gene expression profile (Figure 3a) . Interestingly, both factors presented a similar expression pattern in all the 27 cases. Indeed, the six samples expressing the highest cyclin B mRNA (4.8 ± 0.8) and the six with the lowest (0.9 ± 0.2) were also characterized respectively by the highest and lowest survivin gene expression (4.9 ± 0.8 and 1.1 ± 0.6). Therefore, we individualized two subsets of DLBCL characterized by the level of survivin and cyclin B expression (Figure 3c ). Survivin and cyclin B high expresser cases presented an elevated expression of cyclin A as well as genes encoding for anti-apoptotic factors. Conversely, the expression of all those genes was found decreased for low expresser cases.
We then asked if the same type of gene expression profile could be obtained with a low grade lymphoma control, such as follicular lymphoma. We showed that survivin and cyclin B were also preferentially expressed in the high grade NHL cases, as well as Bfl-1 (Figure 3b) . Interestingly, this comparison between high and low grade lymphomas seems to be characterized by the weak expression of most factors in DLBCL cases. For instance, cyclin D1, cyclin A1 and Bcl-w presented the lowest score. Moreover, the IAP factors and cell cycle inhibitors were found to be preferentially expressed in the follicular control, except for survivin and p16. Finally, to gain an accurate comparison between low and high grade lymphomas, more precise analyses were required. Nevertheless, we considered them as beyond the scope of our present study and therefore not necessary.
For the gene expression profiling in DLBCL cases, we next asked whether a relationship might exist between cyclin B and 
Large B cell lymphomas with low survivin and cyclin B mRNA present a germinal center-like protein staining
The 12 cases of DLBCL characterized by the lowest and highest cyclin B and survivin expression (Figure 3c ) were analyzed by immunohistochemistry on paraffin embedded tissues (Table 3) . Both Bcl-6 and CD10 protein expression, two wellestablished germinal center markers, 9,38-40 were also analyzed besides cyclin B1 protein. The six tumors presenting the lowLeukemia est cyclin B mRNA expression had clear CD10 staining on the neoplastic cell surface associated with Bcl-6 protein expression in more than 50% of the cells. In contrast, lymphomas expressing high levels of cyclin B mRNA were found to be negative or faint for both CD10 and Bcl-6 proteins except for two tumors (cases C3 and C4), obviously Bcl-6 positive, but without CD10 protein expression (Table 3) . Additionally, the cyclin B1 protein staining did not correlate perfectly with the gene expression in the 12 analyzed cases, eg for cases C3, C4 or C16. In both cyclin B expression subgroups, discrepancies were found, emphasizing the fact that gene expression level does not necessarily predict the abundance of functional protein.
In addition, we performed immunostaining of p53, Bcl-2 Table 3 Protein expression analysis by immunohistochemistry on paraffin-embedded tissues from two subgroups of DLBCL defined by their cyclin B gene expression profile *Relative gene expression compared to nonneoplastic lymph node mRNA expression. **Picture original magnification: ×32 or ×80.
and Ki67, three markers considered as poor prognostic factors in aggressive lymphomas, [41] [42] [43] for the 12 selected tumors. Only three tumors presented significant p53 staining but all of them expressed high cyclin B and survivin mRNA (Table 3) . For Bcl-2 protein and Ki67, both expressions were almost identical in the two subgroups. However, we observed that the Bcl-2 protein was detected in all neoplastic tissue from tumors expressing high levels of cyclin B and survivin.
Taken together, our results suggest that high expression of cyclin B and survivin is related to the so-called B-activated form of large B cell lymphoma characterized by a poor prognostic outcome for patients. In our study, we were nevertheless unable to find statistical differences between patients presenting high or low levels of both cyclin B and survivin in terms of overall survival or patients' clinical characteristics before treatment (data not shown).
At this point in the study we suspected a possible relationship between the G2 cell cycle-related cyclin B and the IAP factor survivin. Therefore, with statistical analyses, we tested whether a linear relationship exists between the mRNA expression of these two factors in the 27 DLBCL cases.
Survivin and cyclin B expressions are intimately related in large B cell lymphomas
In order to detect possible relationships between different factors involved either in cell cycle or apoptosis control, a correlation matrix was established with the GAPDH-normalized gene expression results obtained from the 34 selected genes. Using correlation coefficients between pairs of variables, we individualized gene clusters significantly related to one or several dependent variables. Considering survivin or cyclin B as dependent variables, we found an almost identical relationship pattern for both variables (Table 4) . However, for the cell Table 4 Positive relationship between either survivin or cyclin B gene expression and tested genes from 27 DLBCL . Interestingly, as with the first t-test analysis (Table 2) , a significant association was found between gene expression of cyclin A or B and survivin (Table 4 ). In addition, cyclin A and B together showed a high correlation coefficient (0.838, P Ͻ 0.001) suggesting a shared up-regulation response in DLBCL. A significant relationship was found between cyclin B and IAP factors as well as Bcl-w or Bcl-xL belonging to the anti-apoptotic Bcl-2 family of genes. Nevertheless, only cyclin A, Bfl-1 and survivin were closely and strongly related to cyclin B (P Ͻ 0.001). Conversely, when we took survivin as the variable, we confirmed that cyclin A and B presented the highest correlation followed by Bfl-1 and in the third row XIAP, Bcl-w and Bcl-xL.
We then decided to determine whether survivin establishes a preferential relationship with one or several of the tested factors. We used a multiparametric logistic regression model. Survivin results were dichotomized according to the median value and tested against the following variables: cyclin A, cyclin B, Bfl-1, Bcl-xL and XIAP. Because of the number of tested cases, we obtained only one step of the analysis. Cyclin B emerged from this statistical model thus confirming the preferential relationship between survivin and cyclin B; Exp (B) = 1.071 (1.01-1.13, 95% CI), P = 0.017. Overlay scatterplot comparing survivin and cyclin B relative gene expressions through x-y pairs analysis confirmed and illustrated graphically the intimate relationship between the two factors ( Figure 4 ).
Discussion
In this study we analyzed the expression of 34 genes, from 27 large B cell lymphomas, compared to the expression of the mitotic apoptosis inhibitor, survivin. Based on the RNase protection assay, we report the recognition of a subset of DLBCL
Figure 4
Overlay scatterplot comparing survivin and cyclin B gene expressions. Identification of a statistically significant linear relationship. x-y pairs analysis for survivin and cyclin B relative gene expression. R 2 correlation coefficient is indicated.
Leukemia characterized by dual survivin and cyclin B over-expression and its segregation from the activated B-like phenotype. Furthermore, we found that survivin and cyclin B expression in the 27 cases are intimately linked, suggesting that both factors act in synergy to promote G2/M cell cycle transition. Functional analysis of this collaboration in the deregulation of G2/M progression has to be performed to complete this descriptive study. The expression of 34 genes divided into four categoriescell cycle inhibitors, cyclins, Bcl-2 family and IAP factorswas explored. Using the phosphoimager quantification based on a 65 000-unit scale, we could accurately determine gene expression and carry out statistical analyses. All 27 selected large B cell lymphoma cases presented standard clinical characteristics, with 52% probability of 3-year overall survival. Patient distribution for survivin expression was not homogeneous, thus explaining the difference between mean and median value (63 vs 56). The patient cohort was split into two subgroups depending on the median value, and both ttest and non-parametric analysis showed that high expression of survivin was associated with a significant increase of cell cycle activators, cyclin A and B, as well as anti-apoptotic factors Bfl-1, Bcl-w, Bcl-xL and XIAP. All these factors may be involved in a shared enhancement of cell proliferation. In this context the associated increase of pRb 107 , p53 and p27 transcripts in the survivin high expresser subgroup may be due to a feedback regulating loop in response to the high proliferation rate.
Our gene expression profile, obtained by comparison with hyperplasic lymph nodes as control, revealed that survivin over-expression is not an isolated event but rather associated with cyclin B, creating a double peak pattern. Interestingly, survivin and cyclin B expressions were also found elevated using follicular lymphoma as control, but without a double peak pattern. They were not as high as the strong Bfl-1 expression suggesting that this transcript, like cyclin B and survivin, might be specifically linked to aggressive forms of lymphoma. In contrast Bcl-xL, another bcl-2 gene family member, did not show a homogeneous increase.
Gene expression profiling showed an under-expression of many transcripts and, in particular, genes encoding for cell cycle inhibitors. The under-expression may be due to the choice of hyperplasic lymph nodes as control. This type of tissue includes mixed cell populations with numerous activated T and B cells which may present high gene expression levels, as described for p53. 44 Usually, studies testing several hundreds of gene expressions use different types of B cell tissues as control in order to avoid the over-representation of one tissue type. 9 By using pooled RNA extracted from hyperplasic lymph nodes, we specifically asked which genes were differentially expressed when comparing neoplastic and nonneoplastic enlarged lymph nodes. By proceeding in the same manner, and using follicular lymphoma as control, we compared low and high grade lymphoma entities. The underexpression of several cell cycle inhibitors found with both controls may illustrate a specific gene expression pattern related to large B cell lymphomas. In addition, some G1 phase-dependent cyclins were also found always underexpressed in both comparisons. The most striking example concerns cyclin D1, strongly expressed in follicular lymphomas, but not so, in large B cell lymphomas. In this context cyclin D1 over-expression may be a good marker for distinguishing low grade from high grade lymphoma entities. [45] [46] Using gene expression profiles based on both cyclin B and survivin, we identified two subsets of DLBCL disease. Concur-rently with RPA, immunohistochemistry confirmed cyclin B expression and showed that both p53 and Bcl-2 proteins, considered as poor prognosis markers, were significantly present in cyclin B high expresser cases and less so in DLBCL cases expressing low amounts of cyclin B. [41] [42] [43] Conversely, in the latter group, Bcl-6 and CD10, two well-established germinal center markers were highly expressed. [38] [39] [40] These findings corroborate the two distinct DLBCL subgroups described by Alizadeh et al 9 defined by gene expression profiling: the germinal center B-like DLBCL form with good prognosis presents both high Bcl-6 and CD10 expression and low expression of genes involved in cell proliferation and apoptosis inhibition, including Cyclin B and Bcl-2, respectively. This is in contrast to the activated B-like DLBCL form with a poor prognostic outcome.
Our study investigates the dissection of the cell death pathway, efforts that may lead to new therapeutic applications of apoptosis manipulation, including caspase inhibition or sensitization of cancer cells by modulation of survival signals and viral transfer of apoptosis promoting genes. 47 Indeed, survivin was first characterized by its caspase inhibition activity and thus classified as an IAP family protein. 27, 48 However, the cell cycle-regulated expression of this factor proved that survivin is necessary to counteract a default induction of apoptosis in G2/M phase. 29 In recent reports, survivin has been described as a kinetochore-associated passenger protein playing an important function in the mechanism of cell cleavage, 31 and survivin effects have been connected to the promotion of cell proliferation and cell viability mainly through its activation by the p34 cdc2 -cyclin B complex. 30, 49, 50 Therefore, in the context of cancer-related survivin over-expression, the comparison between expression of this factor and cyclins, bcl-2 family genes as well as IAP factors, may tell us whether survivin expression takes place in a broad anti-apoptotic process or is involved in cell cycle promotion. Our multivariate statistical approach demonstrates a preferential relationship between survivin and cyclin B gene expression that emphasizes the role of survivin on the cell cycle level in large B cell lymphomas.
The specific relationship between survivin and cyclin B highlights G2-M transition promotion. 29 Interestingly, we may contrast this finding concerning DLBCL with the G1-related cyclin D1 over-expression that we found in low-grade lymphomas through the gene expression profiling, that previous studies have shown an over-expression of both pRb 105 and cyclin D1 in those neoplasia. 45, 46 Conversely, we have described a constant diminished expression of low-grade lymphomas suggests a specific G1/S transition promotion in these factors in the DLBCL cases. Therefore, our data suggest that cyclin B over-expression linked to survivin over-expression in aggressive forms of lymphoma might represent a specific G2/M transition promotion. 51 
